Last reviewed · How we verify
NCT05349279: QPRECIOUS
Qatar PREgnancy Covid-19 OUtcome Study
trial in COVID-19 in 4,000 participants. Status unknown.
15 April 2023
Quick facts
| Lead sponsor | Hamad Medical Corporation |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 4,000 |
| Start date | 25 May 2021 |
| Primary completion | 15 April 2023 |
| Estimated completion | 15 April 2023 |
| Sites | 1 location across Qatar |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Pregnant Women — all drugs for Pregnant Women →
Sponsor
Hamad Medical Corporation — full company profile →
Who can join
Adults 18 to 50, female only, with COVID-19 or Pregnant Women. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The in-utero exposure of acute viral infection in some instances is proven to have short- and long-term neonatal effects during the postnatal and childhood period and the Zika virus, measles, mumps, and rubella are few examples. COVID-19 is caused by a novel coronavirus strain of unknown consequences. The main purpose of this registry is to collect baseline data and help to establish future studies and hypothesis generation. In addition, we will be exploring the psychological impact of COVID-19 on women during the pregnancy and postnatal period. Stress and anxiety level are increased with potential adverse pregnancy and/or neonatal outcomes especially during an infectious disease outbreak. In fact, COVID-19 is associated with adverse maternal and neonatal outcomes resulting in increased levels of stress and anxiety. In addition, women during the pregnancy, peripartum, and postpartum period are at increased risk of depression. A risk that has been aggravated by social and physical isolation. Indeed, the social and physical isolation, a critically needed measure to stop the virus transmission, resulted in increased stress and depression levels and adversely affecting the mental and physical health of both the mother and the baby.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05349279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Hamad Medical Corporation trials
Trials by the same sponsor.
- NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
- NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
- NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
- NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
- NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05349279 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
- Last refreshed: 20 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing